Kathleen Weisel1, Scott Berger1, Katie Thorn2, Peter C Taylor3, Charles Peterfy4, Hilary Siddall5, Debra Tompson6, Susanne Wang1, Emilia Quattrocchi2, Susan W Burriss1, Jochen Walter7, Paul Peter Tak6,8,9. 1. GlaxoSmithKline, Collegeville, PA, USA. 2. GlaxoSmithKline, Stockley Park, Uxbridge, UK. 3. Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. 4. Spire Sciences, Inc., Boca Raton, FL, USA. 5. GlaxoSmithKline Medicine Research Center, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK. hilary.x.siddall@gsk.com. 6. GlaxoSmithKline Medicine Research Center, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK. 7. Rheumatologische Schwerpunktpraxis, Rendsburg, Germany. 8. Present address: Cambridge University, Cambridge, UK. 9. Present address: Ghent University, Ghent, Belgium.
Abstract
BACKGROUND: Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study evaluated the safety, pharmacokinetics (PK), and preliminary efficacy of GSK2982772, a RIPK1 inhibitor, in moderate to severe rheumatoid arthritis (RA). METHODS:Patients with moderate to severe RA who had received ≥12 weeks' stable-dose conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy were randomized (2:1) to GSK2982772 60 mg or placebo orally 2 or 3 times daily for 84 days. Safety, PK, disease activity, joint damage, and pharmacodynamic (PD) biomarkers were assessed at days 43 and 85. RESULTS:A total of 52 patients were randomized (placebo, 18; GSK2982772, 34). Adverse events (AEs) were reported in 13 (72%) in patients in the placebo group (n = 3 b.i.d; n = 10 t.i.d.) and 20 (61%) in the GSK2982772 group (n = 3 b.i.d; n = 17 t.i.d.). All treatment-related AEs were mild/moderate, except one severe case of alopecia areata at day 49 and retinal vein thrombosis at day 66 (which led to withdrawal from the study) in patients receiving GSK2982772 t.i.d. Disease Activity Score in 28 Joints-C-reactive protein (DAS28-CRP) scores, ACR20/50/70 response, and rates of low disease activity and remission were similar between placebo and GSK2982772 arms. CONCLUSIONS: These results suggest that inhibition of RIPK1 activity at the GSK2982772 exposure levels evaluated do not translate into meaningful clinical improvement of RA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02858492 . Registered 8 August 2016.
RCT Entities:
BACKGROUND:Receptor-interacting protein kinase 1 (RIPK1) is a key mediator of inflammation through cell death and proinflammatory cytokine production. This multicenter, randomized, double-blind (sponsor-unblinded), placebo-controlled, experimental medicine study evaluated the safety, pharmacokinetics (PK), and preliminary efficacy of GSK2982772, a RIPK1 inhibitor, in moderate to severe rheumatoid arthritis (RA). METHODS:Patients with moderate to severe RA who had received ≥12 weeks' stable-dose conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy were randomized (2:1) to GSK2982772 60 mg or placebo orally 2 or 3 times daily for 84 days. Safety, PK, disease activity, joint damage, and pharmacodynamic (PD) biomarkers were assessed at days 43 and 85. RESULTS: A total of 52 patients were randomized (placebo, 18; GSK2982772, 34). Adverse events (AEs) were reported in 13 (72%) in patients in the placebo group (n = 3 b.i.d; n = 10 t.i.d.) and 20 (61%) in the GSK2982772 group (n = 3 b.i.d; n = 17 t.i.d.). All treatment-related AEs were mild/moderate, except one severe case of alopecia areata at day 49 and retinal vein thrombosis at day 66 (which led to withdrawal from the study) in patients receiving GSK2982772 t.i.d. Disease Activity Score in 28 Joints-C-reactive protein (DAS28-CRP) scores, ACR20/50/70 response, and rates of low disease activity and remission were similar between placebo and GSK2982772 arms. CONCLUSIONS: These results suggest that inhibition of RIPK1 activity at the GSK2982772 exposure levels evaluated do not translate into meaningful clinical improvement of RA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02858492 . Registered 8 August 2016.
Entities:
Keywords:
Pharmacodynamics; Pharmacokinetics; RIPK1; Receptor-interacting protein kinase 1; Rheumatoid arthritis
Authors: Josef S Smolen; Aileen L Pangan; Paul Emery; William Rigby; Yoshiya Tanaka; Juan Ignacio Vargas; Ying Zhang; Nemanja Damjanov; Alan Friedman; Ahmed A Othman; Heidi S Camp; Stanley Cohen Journal: Lancet Date: 2019-05-23 Impact factor: 79.321
Authors: V J Palombella; E M Conner; J W Fuseler; A Destree; J M Davis; F S Laroux; R E Wolf; J Huang; S Brand; P J Elliott; D Lazarus; T McCormack; L Parent; R Stein; J Adams; M B Grisham Journal: Proc Natl Acad Sci U S A Date: 1998-12-22 Impact factor: 11.205
Authors: Roy Fleischmann; Joel Kremer; John Cush; Hendrik Schulze-Koops; Carol A Connell; John D Bradley; David Gruben; Gene V Wallenstein; Samuel H Zwillich; Keith S Kanik Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245
Authors: Ronald F van Vollenhoven; Roy Fleischmann; Stanley Cohen; Eun Bong Lee; Juan A García Meijide; Sylke Wagner; Sarka Forejtova; Samuel H Zwillich; David Gruben; Tamas Koncz; Gene V Wallenstein; Sriram Krishnaswami; John D Bradley; Bethanie Wilkinson Journal: N Engl J Med Date: 2012-08-09 Impact factor: 91.245
Authors: Mikkel Østergaard; Charles G Peterfy; Paul Bird; Frédérique Gandjbakhch; Daniel Glinatsi; Iris Eshed; Espen A Haavardsholm; Siri Lillegraven; Pernille Bøyesen; Bo Ejbjerg; Violaine Foltz; Paul Emery; Harry K Genant; Philip G Conaghan Journal: J Rheumatol Date: 2017-08-15 Impact factor: 4.666
Authors: Patrice N Wagner; Qiong Shi; Christi T Salisbury-Ruf; Jing Zou; Michael R Savona; Yuri Fedoriw; Sandra S Zinkel Journal: Blood Date: 2018-11-09 Impact factor: 22.113
Authors: Björn Gerlach; Stefanie M Cordier; Anna C Schmukle; Christoph H Emmerich; Eva Rieser; Tobias L Haas; Andrew I Webb; James A Rickard; Holly Anderton; Wendy W-L Wong; Ueli Nachbur; Lahiru Gangoda; Uwe Warnken; Anthony W Purcell; John Silke; Henning Walczak Journal: Nature Date: 2011-03-31 Impact factor: 49.962
Authors: Maurits F J M Vissers; Jules A A C Heuberger; Geert Jan Groeneveld; Jerome Oude Nijhuis; Peter Paul De Deyn; Salah Hadi; Jeffrey Harris; Richard M Tsai; Andres Cruz-Herranz; Fen Huang; Vincent Tong; Rebecca Erickson; Yuda Zhu; Kimberly Scearce-Levie; Jennifer Hsiao-Nakamoto; Xinyan Tang; Megan Chang; Brian M Fox; Anthony A Estrada; Robert J Pomponio; Miguel Alonso-Alonso; Moshe Zilberstein; Nazem Atassi; Matthew D Troyer; Carole Ho Journal: Clin Transl Sci Date: 2022-06-01 Impact factor: 4.438